Impaired bladder emptying can be caused by chronic conditions such as bladder outlet obstruction in men with benign prostatic hyperplasia and impaired detrusor contractility in patients of either sex.
Some of the established causes of detrusor underactivity include neurogenic, myogenic, aging, and medication side effects.
3) The medical treatment for detrusor underactivity aims to enhance detrusor contractility and to reduce urethral outlet resistance thereby improving voiding. Standard pharmacotherapy includes the use of a-adrenoceptor antagonists to reduce outlet resistance, muscarinic agonists, and acetylcholinesterase (AChE) inhibitors.
Pharmacotherapy using cholinomimetic drugs such as muscarinic agonists and AChE inhibitors has been used to treat impaired bladder emptying 4, 5) since these drugs improve detrusor contractility by activating the parasympathetic cholinergic system. AChE inhibitors are considered to increase detrusor contractility by inactivating cholinesterase, thus maintaining cholinergic stimulation. Alternatively, the potential interaction of AChE inhibitors with cholinergic receptors has been also implicated in the therapeutic and/or side-effects associated with this class of compounds. 6, 7) It was previously shown that neostigmine interacts directly with muscarinic and nicotinic receptor sites. [6] [7] [8] Distigmine bromide (distigmine) (Fig. 1) , a reversible and long-acting carbamate cholinesterase inhibitor, has been clinically used to treat patients with voiding dysfunction associated with impaired detrusor contractility. [9] [10] [11] Bougas et al. 9) reported that treatment with distigmine resulted in a statistically significant reduction in residual volume and percentage residual volume, obviating the need for intermittent selfcatheterization in patients with detrusor underactivity. In addition, the maximum flow rate and detrusor pressure at maximum flow increased. These results suggested that distigmine has clinical efficacy in patients with detrusor underactivity. 9) Horinouchi et al. 12) revealed that distigmine significantly potentiated acetylcholine (ACh)-induced contractions of the April 2010 653
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Taketsugu HARADA, a Kazumi FUSHIMI, a Aya KATO, a Yoshihiko ITO, a Saori NISHIJIMA, isolated bladder detrusor smooth muscle of guinea-pigs and that it directly contracted the detrusor. However, despite clinical and in vitro experimental evidence indicating that distigmine increases detrusor contractility, the precise mechanism underlying the pharmacological effects of this agent including its potential interaction with cholinergic receptors remains to be still clarified. The present study was undertaken to examine using radioreceptor binding assay whether distigmine binds directly to muscarinic and nicotinic receptors since these receptors play a significant role in the bladder voiding function. The effect of distigmine was also compared with that of neostigmine and donepidil (Fig. 1) , clinically used AChE inhibitors. Animals Male Sprague-Dawley rats (Japan SLC, Shizuoka, Japan) aged 8-10 weeks were used in this study. The rats were housed in the laboratory with free access to food (MF; Oriental East, Tokyo, Japan) and water and maintained under a 12-h dark/light cycle in a room at controlled temperature (24Ϯ1°C) and humidity (55Ϯ5%). Then, the rats were exsanguinated by bleeding them from the descending aorta under temporary anesthesia with diethyl ether. The bladder, submaxillary gland and cerebral cortex were then dissected and the tissues were minced with scissors.
MATERIALS AND METHODS

Materials
Muscarinic Receptor Binding Assay The radioligandbinding assays for muscarinic receptors were performed using the antagonistic radioligand [ 3 H]oxotremorine-M), the reaction was terminated by rapid filtration through Whatman GF/ B glass fiber filters (presoaked in 0.05% polyethyleneimine in the case of [ 3 H]oxotremorine-M), and the filters were rinsed with ice-cold buffer. Tissue-bound radioactivity was extracted from the filters by immersion in scintillation fluid, and radioactivity was determined by a liquid scintillation counter. Specific binding was determined experimentally from the difference between counts in the absence and presence of 1 mM atropine.
Nicotinic Receptor Binding Assay The radioligandbinding assays for nicotinic receptors were performed using [ 3 H]epibatidine. 15) The cerebral cortex was homogenized in 19 volumes of ice-cold 50 mM Tris-HCl buffer (pH 7.4) and the homogenate was centrifuged at 40000ϫg for 10 min at 4°C. The resulting pellet suspension was further centrifuged at 40000ϫg for 10 min at 4°C, and the suspension of the resulting pellet mixed with 19 volumes of 50 mM Tris-HCl buffer was incubated at room temperature for 1 h. In the inhibition experiments, the homogenate of cerebral cortex was incubated with [ 3 H]epibatidine (0.1 nM) in the presence of various concentrations of AChE inhibitors. Incubation was carried out for 60 min at 25°C. The reaction was terminated by rapid filtration through Whatman GF/B glass fiber filters presoaked in 0.05% polyethyleneimine, and the filters were rinsed with ice-cold buffer. Tissue-bound radioactivity was extracted from the filters by immersion in scintillation fluid, and radioactivity was determined by a liquid scintillation counter. Specific binding was determined experimentally from the difference between counts in the absence and presence of 30 mM (Ϫ)-nicotine hydrogen tartrate.
Measurement of AChE Activity
The measurement of AChE activity of whole blood cells with or without AChE inhibitor was carried out according to the method previously reported by Worek et al. 16) Briefly, whole blood dilutions were prepared from freshly heparinized blood samples by adding 100 ml to 10 ml ice-cold diluting reagent (0.1 mM phosphate buffer with 0.03% TritonX-100, pH 7.4). After careful mixing, the samples were frozen immediately (Ϫ30°C) and kept until the analysis. For the determination of AChE activity, diluted blood samples (1.5 ml) had 1.5 ml of 100 mM phosphate buffer (pH 7.4) containing 0.32 mM 5,5Ј-dithio-bid-2-nitrobenzoate (DTNB) and 0.02 mM ethopropadine added to them and were incubated for 10 min at 37°C with or without AChE inhibitors. Then, 0.05 ml of 28.3 mM acetylthiocholine was added, and the absorbance at 436 nm and 37°C was measured every 3 min for 9 min, before the reaction velocities were calculated. For the determination of total hemoglobin, 1.4 ml of the blood dilution was mixed with 1.4 ml of the transformation solution (0.3 mM potassium ferricyanide, 0.4 mM potassium cyanide, and 6.0 mM sodium bicarbonate in distilled water and 0.05% v/v) Triton X-100) and incubated for 10 min at ambient temperature. The absorbance at 546 nm was read and AChE activity was normalized to the hemoglobin content of the sample.
Data Analysis Binding data were subjected to a nonlinear regression analysis using Graph Pad PRISM (ver. 4, Graph Pad Software, San Diego, CA, U.S.A.) as previously noted.
17) The ability of the drugs to inhibit specific binding of radioligand was estimated from their IC 50 values; i.e., the molar concentration of the unlabeled drug necessary to dis-place 50% of the specific binding of radioligand. The inhibition constant K i was calculated from the equation 
RESULTS
Inhibition of Acetylcholinesterase Activity
Distigmine (3-300 nM), neostigmine (1-100 nM), and donepezil (3-300 nM) inhibited AChE activity in the rat blood in a concentration-dependent manner (Fig. 2) . The IC 50 values for distigmine, neostigmine, and donepezil were 45.0Ϯ2.0, 6.9Ϯ0.3, and 28.2Ϯ1.3 nM, respectively, indicating that neostigmine is a relatively potent inhibitor of AChE.
Muscarinic Receptor Binding Activity in Bladder, Submaxillary Gland and Cerebral Cortex Distigmine (30 nM-30 mM), neostigmine (100 nM-100 mM), and donepezil (100 nM-10 mM) inhibited specific [ 3 H]NMS binding in the bladder (Fig. 3A) , submaxillary gland, and cerebral cortex in a concentration-dependent manner. The K i value for distigmine in the bladder was significantly (2 to 3-fold) lower than those in the submaxillary gland and cerebral cortex ( Table 1) . The K i values for distigmine in each tissue were 2 to 3-fold higher than those for donepedil. The K i values for neostigmine in each tissue were more than 50 mM.
Similarly, distigmine (30 nM-10 mM), neostigmine (100 nM-100 mM), and donepezil (10 nM-10 mM) inhibited specific [
3 H]oxotremorine-M binding in the bladder (Fig. 3B ), submaxillary gland, and cerebral cortex of rats in a concentration-dependent manner. The K i values for distigmine did not differ significantly among tissues (Table 1) . They were roughly similar to those for donepedil and significantly (6 to 48-fold) lower than those for neotigmine. Neostigmine and donepedil showed considerably higher affinity for the [ 3 H]oxotremorine-M binding sites in the cerebral cortex than those in the bladder and submaxillary gland. Table 1) .
Analysis of binding parameters in the presence of each agent at concentrations representing the IC 50 values for the inhibition of radioligand binding (Fig. 3A) revealed that distigmine (2-7 mM) and donepidil (1-4 mM) had significantly The rat blood samples were incubated with different concentrations of distigmine (᭹), neostigmine (ᮀ), and donepezil (᭝) as described in Materials and Methods. Each point represents the meanϮS.E. for three to five experiments. nificant effect on the B max values (Table 3) .
Nicotinic Receptor Binding in the Cerebral Cortex As shown in Fig. 3C , distigmine, neostigmine, and donepezil (each: 100 nM-100 mM) inhibited specific [ 3 H]epibatidine binding in the rat cerebral cortex in a concentration-dependent manner. The K i value for distigmine (22.9Ϯ3.3 mM) was equivalent to the values for neostigmine (18.8Ϯ3.3 mM) and donepezil (30.3Ϯ2.1 mM).
Effects of Repeated Treatment with Distigmine on Muscarinic Receptors in the Rat Bladder
Following repeated oral administration of distigmine at the dose of 1.0 mg/kg, twice a day for 14 d, blood AChE activity was markedly (52%) reduced. In these rats, there were significant (40% and 21%, respectively) decreases in the B max values for (Table 4 ). The decrease in B max was significantly greater in the bladder than the submaxillary gland. On the other hand, in the cerebral cortex of the distigminetreated rats, there was little significant alteration in the muscarinic receptor binding parameters.
DISCUSSION
The major findings of this study are that 1) distigmine directly binds to muscarinic and nicotinic receptors in the rat tissues with higher affinity for the former, 2) donepezil dis- Rats orally received distigmine (1.0 mg/kg) or vehicle (control) twice a day for 14 d. The homogenates of rat tissues were used to estimate [ plays similar receptor binding activities to distigmine while neostigmine has much lower binding affinity for muscarinic receptors, and 3) repeated oral administration of distigmine causes downregulation of muscarinic receptors in the bladder and submaxillary gland but not cerebral cortex of rats.
In the current study, distigmine, neostigmine, and donepezil were confirmed to inhibit AChE activity in the rat blood, and the inhibitory effect of distigmine was not much different from that of donepedil and significantly weaker than that of neostigmine. It was found that distigmine, neostigmine, and donepezil competed for specific [ 3 H]NMS binding sites in the bladder, submaxillary gland, and cerebral cortex of rats, indicating significant binding activity of muscarinic receptors. The binding affinity of distigmine was significantly higher in the bladder than in other tissues ( Table 1 Also, distigmine displayed significant binding activity with nicotinic receptors in the rat cerebral cortex, and its affinities for them were considerably lower than its binding affinity for muscarinic receptors. Similar results were observed for neostigmine and donepedil.
Drug-receptor binding characteristics are generally analyzed by saturation isotherms of radioligand binding. 19 It is known that muscarinic receptors undergo compensatory regulation following significant changes in cholinergic neuronal activity. [20] [21] [22] [23] Yamada et al. 20, 21) found that downregulation of muscarinic agonists occurred in the brain, ileum, and striatum of rats after repeated treatment with an organophosphorus AChE inhibitor, diisopropylfluorophosphate (DFP). In the current study, repeated oral administration of distigmine caused a significant decrease in the B max values for specific [ 3 H]NMS binding in the bladder and submaxillary gland. The downregulation of muscarinic receptors was significantly greater in the former tissue. On the other hand, in the cerebral cortex of these distigmine-treated rats, there was little significant alteration in muscarinic receptor binding parameters, suggesting poor permeability of this agent through the blood-brain barrier. These results imply that distigmine administered orally binds preferentially to muscarinic receptors in the bladder, clinically targeted organ. It is likely that the observed decrease in muscarinic receptor density induced by distigmine reflects downregulation of bladder muscarinic receptors by excessive cholinergic stimulation, which results from chronically low AChE levels. In addition, the involvement of direct stimulation of muscarinic receptors by distigmine is also assumed. This idea may be consistent with the finding of Yamada et al. 20, 21) who indicated a significant involvement of cholinergic nerves in physiological functions in the urinary bladder. Taken together, the observed direct interaction of distigmine with the bladder muscarinic receptors may contribute partly to the therapeutic and/or side effects seen in the treatment of detrusor underactivity.
